Study of an experimental drug with or without immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug called SHR-1826, either alone or combined with an immunotherapy (a treatment that boosts your immune system to fight cancer), for people with advanced liver cancer who have already tried other treatments and they stopped working. The goal is to see if this new drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with hepatocellular carcinoma (the most common kind of liver cancer) and it cannot be removed with surgery.
- You must have already tried at least one standard treatment for your cancer, and it did not work or caused bad side effects.
- You must have at least one tumor that can be seen and measured on an imaging test.
- You must be expected to live at least 12 weeks (about 3 months) from the start of the study.
- You cannot have serious liver problems (like fluid in the belly, bleeding, confusion, or kidney failure), brain metastases, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs given before and after surgery for liver cancer that can be removed. The goal is to see if this approach can help reduce the chance of the cancer coming back.
This trial tests a new drug, SHR-4506, for people with advanced cancers that have stopped responding to standard treatments or cannot be treated with standard options. It aims to see if the drug is safe and helpful.
This study tests a combination of two immunotherapy drugs (IMM2510 and IMM27M) for advanced liver cancer. The goal is to see if this combination is safe and effective in shrinking tumors and helping people live longer.
This trial tests a new drug called SHR-1826 for people with advanced solid tumors that have not responded to or are no longer helped by standard treatments. It is an early-phase study (Phase 1) to see if the drug is safe and how well it works.
Hear when a new Hepatocellular Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.